X

Xilio Therapeutics, Inc. (XLO)

NCM – Real Time Price. Currency in USD

7.73

0.00 (0.00%)

At close: May 12, 2026, 4:00 PM EDT

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Xilio Therapeutics, Inc. (XLO)

NCM – Real Time Price. Currency in USD

7.73

0.00 (0.00%)

At close: May 12, 2026, 4:00 PM EDT

12.05.2026

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.

12.05.2026

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

07.05.2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

17.04.2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models

16.04.2026

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.

03.04.2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

01.04.2026

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

07.05.2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.

17.04.2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models

16.04.2026

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.

Search stocks

Xilio Therapeutics, Inc. (XLO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.